Cambridge AI-Designed Broad-Spectrum Bird Flu Vaccine Shows Protection in Animals

The significance here is less the animal-trial result than the method: designing a candidate around conserved features across many virus sequences is an attempt to get ahead of variant turnover rather than chase it, which is the core problem with seasonal flu vaccines. It matters most for poultry producers and public-health bodies weighing stockpile strategies, and for the university spin-off seeking to move the platform beyond proof of concept. The open questions are whether protection in animals holds up in human trials, how durable and truly broad the coverage proves, and whether regulators can assess an AI-designed candidate on a comparable timeline.